TWI906204B - 用於治療及預防肌肉萎縮性脊髓側索硬化症之組合物及方法 - Google Patents

用於治療及預防肌肉萎縮性脊髓側索硬化症之組合物及方法

Info

Publication number
TWI906204B
TWI906204B TW108144617A TW108144617A TWI906204B TW I906204 B TWI906204 B TW I906204B TW 108144617 A TW108144617 A TW 108144617A TW 108144617 A TW108144617 A TW 108144617A TW I906204 B TWI906204 B TW I906204B
Authority
TW
Taiwan
Prior art keywords
dose
antisense oligonucleotide
administered
pharmaceutical composition
loading
Prior art date
Application number
TW108144617A
Other languages
English (en)
Chinese (zh)
Other versions
TW202035694A (zh
Inventor
伊凡 亞歷山德羅夫 內斯托羅夫
托比 弗格森
丹尼爾 A 諾里斯
Original Assignee
美商百健Ma公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商百健Ma公司 filed Critical 美商百健Ma公司
Publication of TW202035694A publication Critical patent/TW202035694A/zh
Application granted granted Critical
Publication of TWI906204B publication Critical patent/TWI906204B/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0089—Oxidoreductases (1.) acting on superoxide as acceptor (1.15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3525—MOE, methoxyethoxy
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/35—Special therapeutic applications based on a specific dosage / administration regimen
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y115/00—Oxidoreductases acting on superoxide as acceptor (1.15)
    • C12Y115/01—Oxidoreductases acting on superoxide as acceptor (1.15) with NAD or NADP as acceptor (1.15.1)
    • C12Y115/01001—Superoxide dismutase (1.15.1.1)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
TW108144617A 2018-12-14 2019-12-06 用於治療及預防肌肉萎縮性脊髓側索硬化症之組合物及方法 TWI906204B (zh)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201862779916P 2018-12-14 2018-12-14
US62/779,916 2018-12-14
US201962807603P 2019-02-19 2019-02-19
US62/807,603 2019-02-19
US201962840879P 2019-04-30 2019-04-30
US62/840,879 2019-04-30

Publications (2)

Publication Number Publication Date
TW202035694A TW202035694A (zh) 2020-10-01
TWI906204B true TWI906204B (zh) 2025-12-01

Family

ID=69160351

Family Applications (1)

Application Number Title Priority Date Filing Date
TW108144617A TWI906204B (zh) 2018-12-14 2019-12-06 用於治療及預防肌肉萎縮性脊髓側索硬化症之組合物及方法

Country Status (20)

Country Link
US (1) US20220073930A1 (cg-RX-API-DMAC10.html)
EP (1) EP3894557A1 (cg-RX-API-DMAC10.html)
JP (2) JP7612575B2 (cg-RX-API-DMAC10.html)
KR (2) KR102821047B1 (cg-RX-API-DMAC10.html)
CN (3) CN113330116A (cg-RX-API-DMAC10.html)
AU (2) AU2019396522B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021011334A2 (cg-RX-API-DMAC10.html)
CA (1) CA3115549A1 (cg-RX-API-DMAC10.html)
CL (1) CL2021001136A1 (cg-RX-API-DMAC10.html)
CO (1) CO2021008187A2 (cg-RX-API-DMAC10.html)
CR (1) CR20210384A (cg-RX-API-DMAC10.html)
IL (1) IL283833A (cg-RX-API-DMAC10.html)
JO (1) JOP20210143A1 (cg-RX-API-DMAC10.html)
MX (1) MX2021005086A (cg-RX-API-DMAC10.html)
MY (1) MY209775A (cg-RX-API-DMAC10.html)
PH (1) PH12021551365A1 (cg-RX-API-DMAC10.html)
SG (1) SG11202103415WA (cg-RX-API-DMAC10.html)
TW (1) TWI906204B (cg-RX-API-DMAC10.html)
UY (1) UY38506A (cg-RX-API-DMAC10.html)
WO (1) WO2020123783A1 (cg-RX-API-DMAC10.html)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016040748A1 (en) 2014-09-12 2016-03-17 Ionis Pharmaceuticals, Inc. Compositions and methods for detection of smn protein in a subject and treatment of a subject
JP7506606B2 (ja) 2018-01-25 2024-06-26 バイオジェン・エムエイ・インコーポレイテッド 脊髄性筋萎縮症を治療する方法
MA54383A (fr) 2018-12-06 2021-10-13 Biogen Ma Inc Protéine neurofilamenteuse pour guider une intervention thérapeutique dans la sclérose laterale amyotrophique
EP3924739A1 (en) 2019-02-12 2021-12-22 Biogen MA Inc. Biomarkers of progressive multifocal leukoencephalopathy
KR20230172502A (ko) * 2021-03-31 2023-12-22 바이오젠 엠에이 인코포레이티드 근위축성 측삭경화증의 치료
WO2025045130A1 (zh) * 2023-08-29 2025-03-06 石药集团中奇制药技术(石家庄)有限公司 一种抑制sod1基因表达的dsrna分子及其应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015153800A2 (en) * 2014-04-01 2015-10-08 Isis Pharmaceuticals, Inc. Compositions for modulating sod-1 expression

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005504020A (ja) 2001-07-03 2005-02-10 アイシス・ファーマシューティカルス・インコーポレーテッド ヌクレアーゼ耐性キメラオリゴヌクレオチド
WO2013134403A1 (en) * 2012-03-06 2013-09-12 The Washington University Method of treating neurodegenerative diseases with microrna regulators
SI3119888T1 (sl) * 2014-03-19 2021-11-30 Ionis Pharmaceuticals, Inc. Sestavki za moduliranje izražanja ataksina 2
CN114717264A (zh) 2014-11-14 2022-07-08 沃雅戈治疗公司 治疗肌萎缩性侧索硬化(als)的组合物和方法
EP3618839A4 (en) * 2017-05-05 2021-06-09 Voyager Therapeutics, Inc. COMPOSITIONS AND METHODS OF TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS (ALS)
WO2018218219A1 (en) * 2017-05-26 2018-11-29 University Of Miami Determining onset of amyotrophic lateral sclerosis

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015153800A2 (en) * 2014-04-01 2015-10-08 Isis Pharmaceuticals, Inc. Compositions for modulating sod-1 expression

Also Published As

Publication number Publication date
KR20210131992A (ko) 2021-11-03
MX2021005086A (es) 2021-08-16
JP2022513597A (ja) 2022-02-09
IL283833A (en) 2021-07-29
CO2021008187A2 (es) 2021-09-09
JP2025023319A (ja) 2025-02-14
SG11202103415WA (en) 2021-06-29
CN118987017A (zh) 2024-11-22
MY209775A (en) 2025-08-03
KR20250090384A (ko) 2025-06-19
CL2021001136A1 (es) 2022-01-14
EP3894557A1 (en) 2021-10-20
BR112021011334A2 (pt) 2021-09-08
WO2020123783A1 (en) 2020-06-18
US20220073930A1 (en) 2022-03-10
CA3115549A1 (en) 2020-06-18
JOP20210143A1 (ar) 2023-01-30
UY38506A (es) 2020-06-30
CN119185345A (zh) 2024-12-27
JP7612575B2 (ja) 2025-01-14
CR20210384A (es) 2021-12-20
AU2019396522B2 (en) 2026-04-09
TW202035694A (zh) 2020-10-01
CN113330116A (zh) 2021-08-31
KR102821047B1 (ko) 2025-06-16
AU2026205314A1 (en) 2026-07-23
PH12021551365A1 (en) 2021-11-22
AU2019396522A1 (en) 2021-05-06

Similar Documents

Publication Publication Date Title
KR102821047B1 (ko) 근위축 측삭 경화증의 치료 및 방지를 위한 조성물 및 방법
JP6637121B2 (ja) 被験体におけるsmn2スプライシングのモジュレーションのための組成物および方法
KR102941589B1 (ko) 프리온 발현을 감소시키기 위한 화합물 및 방법
US7622455B2 (en) Methods for slowing familial ALS disease progression
CN106459972A (zh) 用于调节sod‑1表达的组合物
KR20140074997A (ko) 신경병성 질환에서 마이크로rna
KR20260064686A (ko) 올리고뉴클레오타이드 조성물 및 이의 방법
KR20210008498A (ko) Fxi 발현을 감소시키기 위한 화합물 및 방법
KR20210102294A (ko) 근위축성 측삭 경화증에서 치료요법적 중재를 안내하기 위한 신경필라멘트 단백질
RU2824046C2 (ru) Составы для лечения и предотвращения бокового амиотрофического склероза
JP2024511767A (ja) 筋萎縮性側索硬化症の治療
EA051069B1 (ru) Составы и способы лечения и предотвращения бокового амиотрофического склероза
RU2793459C2 (ru) Композиции и способы модуляции smn2 сплайсинга у субъекта
RU2858547C2 (ru) Композиции для модулирования экспрессии sod-1
CN120359038A (zh) 抑制性核酸及其使用方法
CN121358862A (zh) 用于治疗肾脏疾病的组合物和方法